CTOR Citius Oncology, Inc.
USHealthcareAs of 2026-08-24
Why CTOR matters now
Citius Oncology, Inc. (CTOR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.75 with +0.83% on the session and $69.7M in market capitalization; recent performance reads 1-month -19.14% and YTD -33.03%.
The latest financial table shown here is Q2 2026, with revenue of $1.7M, net income of $-26.6M, and EPS of $-0.27. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.1%.
The latest indexable market news headline is "Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.90
P/S
11.10
EV/EBITDA
-1.54
DCF Value
$0.11
FCF Yield
-27.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.1%
Operating Margin
-775.6%
Net Margin
-757.6%
ROE
-99.5%
ROA
-42.2%
ROIC
-103.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.7M | $-26.6M | $-0.27 |
| Q1 2026 | $3.9M | $-5.5M | $-0.06 |
| Q4 2025 | $0.00 | $-5.0M | $-0.06 |
| FY 2025 | $0.00 | $-24.8M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
3.42
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.